Sunday, December 21, 2014

Tuesday Features

Season’s Greetings (and JPM 2015)

Season’s Greetings (and JPM 2015)

Wow! What a great year 2014 turned out to be! On behalf of everyone at BioTuesdays, I would like to wish you all a safe and happy holiday season. After taking a short break to spend time with family and friends, we will be back in full swing with our next Tuesday Feature on January 6. Many of our Featured companies are planning to attend the upcoming... [Read more of this feature]


LED Medical’s meteoric rise in dental imaging

LED Medical’s meteoric rise in dental imaging

With a growing portfolio of digital imaging technology products for the dental sector, LED Medical Diagnostics (OTCQX:LEDIF; TSX-V:LMD; FSE:LME) is positioned to become a leading player in the North American market. David Gane “We are in the right space at the right time,” CEO, Dr. David Gane, says in an interview with BioTuesdays.com. “There... [Read more of this feature]


Avivagen’s OxC-beta as natural alternative to antibiotics

Avivagen’s OxC-beta as natural alternative to antibiotics

Three peer-reviewed research papers published this year by Avivagen (TSX-V:VIV) and independent collaborators, backed up with successful testing in Asia, have put the company in a position to pursue major contracts for its OxC-beta feed supplement as a natural alternative to antibiotics for the livestock industry. Cameron Groome “In OxC-beta, we have... [Read more of this feature]


More Posts From Tuesday Features

Briefs

Feltl starts Joint Corp. at strong buy

Feltl starts Joint Corp. at strong buy

Feltl has initiated coverage of Joint Corp. (NASDAQ:JYNT) with a “strong buy” rating and price target of $12.45. The stock closed at $6.40 on Thursday. “The Joint is poised to further disrupt the chiropractic industry,” writes analyst Brent Rystrom, adding that for the past few years, the company has been growing rapidly as it expanded its low-cost,... [Read more of this brief]


Amarantus in second closing of Series E preferred

Amarantus in second closing of Series E preferred

Amarantus BioScience Holdings (OTCQB:AMBS) has entered into definitive agreements to raise an additional $2-million under its previously announced transaction to issue Series E preferred stock, bringing the total capital raised to $5-million. “In recent months, we have been working towards further strengthening our balance sheet, and I am very... [Read more of this brief]


Nuvo Research finishes Phase 2 WF10 study

Nuvo Research finishes Phase 2 WF10 study

One hundred seventy-nine patients have completed Nuvo Research’s (TSX:NRI) 16-week, double-blind, placebo-controlled, Phase 2 clinical trial to investigate the safety and efficacy of WF10 in patients with refractory allergic rhinitis. The company expects to release the top-line results of the study in mid-February of 2015. In a statement, Dr. Henrich... [Read more of this brief]


Leerink ups OvaScience price target to $56

Leerink ups OvaScience price target to $56

Leerink Partners has raised its price target for “outperform-rated” OvaScience (NASDAQ:OVAS) to $56 from $23 after a company investor event where management announced major achievements for all three products. The stock closed at $34.96 on Wednesday. “Our key takeaways include AUGMENT training cycles (150 vs. 40-to-60) and announced pricing ($15,000-to-$25,000... [Read more of this brief]


HCW starts GenSpera at buy

HCW starts GenSpera at buy

H.C. Wainwright has launched coverage of GenSpera (OTCQB:GNSZ) with a “buy” rating and $2 price target. The stock closed at 61 cents on Tuesday. GenSpera has developed a novel platform to transform a cytotoxin into a targeted prodrug chemotherapy, which “we believe could help the company become a meaningful player in the currently estimated $90-billion... [Read more of this brief]


More Posts From Briefs
Email Newsletters with Constant Contact
Google+